Allergan shares surged in pre-market trading Tuesday after it agreed to a $63 billion takeover from biopharmaceutical group AbbVie. AbbVie will pay $188.24 each in cash and shares for Allergan's outstanding common stock, a 45% premium to the group's Monday closing price, in a deal that would value the Botox maker at around $63 billion.
Trending:
Allergan agrees to $63 billion takeover from AbbVie in blockbuster pharma deal